WhatPeptide

ARA-290

ARA-290 is a non-hematopoietic erythropoietin-derived peptide engineered to activate the innate repair receptor without stimulating red blood cell production, studied for neuropathic pain and tissue repair. Clinical trials have explored its utility in sarcoidosis-related nerve damage and diabetic neuropathy.

Preliminary evidence Unregulated Healing & Recovery

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

Half-life

Approximately 20 minutes SC; biological effects persist hours to days via receptor-mediated signaling

Dosage range

4 mg subcutaneously daily (clinical trial dosing)

Administration

Subcutaneous injection

Research level

Preliminary

How ARA-290 works

ARA-290 selectively binds the heterodimeric innate repair receptor composed of the erythropoietin receptor and the common beta chain, activating cytoprotective and anti-apoptotic signaling cascades distinct from erythropoiesis. This pathway promotes tissue repair, reduces neuroinflammation, and modulates macrophage polarization toward a reparative phenotype. Phase 2 data in sarcoidosis patients suggests measurable improvements in small fiber neuropathy.

Also known as: Cibinetide, ERY-007

Research relevance

Recovery & Healing
Moderate relevance 65
Immune Support
Moderate relevance 50

Side effects & safety

Injection site reactions Headache Fatigue

Contraindications

Erythropoietin hypersensitivity
Pregnancy
Hematologic disorders

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is ARA-290? +
ARA-290 is a non-hematopoietic erythropoietin-derived peptide engineered to activate the innate repair receptor without stimulating red blood cell production, studied for neuropathic pain and tissue repair. Clinical trials have explored its utility in sarcoidosis-related nerve damage and diabetic neuropathy. Its mechanism of action is based on preliminary or early-stage research.
What is ARA-290 researched for? +
ARA-290 has the strongest research relevance for Recovery & Healing, Immune Support. Evidence is based on preliminary or early-stage research.
What are the side effects of ARA-290? +
Reported side effects include Injection site reactions, Headache, Fatigue. Key contraindications: Erythropoietin hypersensitivity; Pregnancy; Hematologic disorders.
Is ARA-290 FDA approved? +
ARA-290 is not FDA-approved. It is available as a research compound or through compounding pharmacies in some jurisdictions.
How is ARA-290 administered? +
ARA-290 is typically administered via subcutaneous route. Researched dosage range: 4 mg subcutaneously daily (clinical trial dosing). Half-life: Approximately 20 minutes SC; biological effects persist hours to days via receptor-mediated signaling.

Explore similar peptides

BPC-157

Animal studies only

Healing & Recovery

A pentadecapeptide derived from human gastric juice that has demonstrated tissue-protective and regenerative properties across multiple animal models.

TB-500

Animal studies only

Healing & Recovery

A synthetic fragment associated with thymosin beta-4 signaling that is studied for migration, remodeling, and tissue repair in preclinical injury models.

KPV

Preliminary evidence

Anti-Inflammatory

A short melanocortin-derived tripeptide studied for anti-inflammatory signaling in gut and skin models. Placed on FDA Category 2 list (September 29, 2023).

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.